Vaccine to Target TSST-1 for Staphylococcus Aureus Infections, Toxic Shock Syndrome and Mycoses is under clinical development by Biomedizinische Forschungsgesellschaft and currently in Phase II for Toxic Shock. According to GlobalData, Phase II drugs for Toxic Shock does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Vaccine to Target TSST-1 for Staphylococcus Aureus Infections, Toxic Shock Syndrome and Mycoses LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vaccine to Target TSST-1 for Staphylococcus Aureus Infections, Toxic Shock Syndrome and Mycoses overview
The recombinant TSST-1 variant vaccine is under development for the treatment of toxic shock syndrome and mycoses. The vaccine candidate is administered through intramuscular route. The vaccine candidate targets toxic shock syndrome toxin 1 (TSST-1).
See Also:
It was also under development for bacterial infections such as Staphylococcus aureus infection and mycoses.
For a complete picture of Vaccine to Target TSST-1 for Staphylococcus Aureus Infections, Toxic Shock Syndrome and Mycoses’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
